ID   KSYK_HUMAN              Reviewed;         635 AA.
AC   P43405;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   10-MAY-2017, entry version 200.
DE   RecName: Full=Tyrosine-protein kinase SYK;
DE            EC=2.7.10.2;
DE   AltName: Full=Spleen tyrosine kinase;
DE   AltName: Full=p72-Syk;
GN   Name=SYK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7513161; DOI=10.1006/bbrc.1994.1409;
RA   Yagi S., Suzuki K., Hasegawa A., Okumura K., Ra C.;
RT   "Cloning of the cDNA for the deleted syk kinase homologous to ZAP-70
RT   from human basophilic leukemia cell line (KU812).";
RL   Biochem. Biophys. Res. Commun. 200:28-34(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND
RP   AUTOPHOSPHORYLATION.
RX   PubMed=8163536;
RA   Law C.-L., Sidorenko S.P., Chandran K.A., Draves K.E., Chan A.C.,
RA   Weiss A., Edelhoff S., Disteche C.M., Clark E.A.;
RT   "Molecular cloning of human Syk. A B cell protein-tyrosine kinase
RT   associated with the surface immunoglobulin M-B cell receptor
RT   complex.";
RL   J. Biol. Chem. 269:12310-12319(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS LONG AND SHORT).
RC   TISSUE=Eye, and Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 6-635.
RC   TISSUE=Tonsil;
RX   PubMed=8168854; DOI=10.1007/BF00189234;
RA   Mueller B., Cooper L., Terhorst C.;
RT   "Molecular cloning of the human homologue to the pig protein-tyrosine
RT   kinase syk.";
RL   Immunogenetics 39:359-362(1994).
RN   [6]
RP   INTERACTION WITH EPSTEIN-BARR VIRUS LMP2A.
RX   PubMed=7895172; DOI=10.1016/S1074-7613(95)80040-9;
RA   Miller C.L., Burkhardt A.L., Lee J.H., Stealey B., Longnecker R.,
RA   Bolen J.B., Kieff E.;
RT   "Integral membrane protein 2 of Epstein-Barr virus regulates
RT   reactivation from latency through dominant negative effects on
RT   protein-tyrosine kinases.";
RL   Immunity 2:155-166(1995).
RN   [7]
RP   INTERACTION WITH VAV1.
RX   PubMed=8986718; DOI=10.1016/S1074-7613(00)80273-3;
RA   Deckert M., Tartare-Deckert S., Couture C., Mustelin T., Altman A.;
RT   "Functional and physical interactions of Syk family kinases with the
RT   Vav proto-oncogene product.";
RL   Immunity 5:591-604(1996).
RN   [8]
RP   FUNCTION IN PHOSPHORYLATION OF PLCG1, AND INTERACTION WITH PLCG1.
RX   PubMed=8657103; DOI=10.1128/MCB.16.4.1305;
RA   Law C.L., Chandran K.A., Sidorenko S.P., Clark E.A.;
RT   "Phospholipase C-gamma1 interacts with conserved phosphotyrosyl
RT   residues in the linker region of Syk and is a substrate for Syk.";
RL   Mol. Cell. Biol. 16:1305-1315(1996).
RN   [9]
RP   FUNCTION IN PHOSPHORYLATION OF CBL, AND INTERACTION WITH CBL.
RX   PubMed=9535867; DOI=10.1074/jbc.273.15.8867;
RA   Deckert M., Elly C., Altman A., Liu Y.C.;
RT   "Coordinated regulation of the tyrosine phosphorylation of Cbl by Fyn
RT   and Syk tyrosine kinases.";
RL   J. Biol. Chem. 273:8867-8874(1998).
RN   [10]
RP   ENZYME REGULATION, AND INTERACTION WITH CBL.
RX   PubMed=9857068; DOI=10.1074/jbc.273.52.35273;
RA   Lupher M.L. Jr., Rao N., Lill N.L., Andoniou C.E., Miyake S.,
RA   Clark E.A., Druker B., Band H.;
RT   "Cbl-mediated negative regulation of the Syk tyrosine kinase. A
RT   critical role for Cbl phosphotyrosine-binding domain binding to Syk
RT   phosphotyrosine 323.";
RL   J. Biol. Chem. 273:35273-35281(1998).
RN   [11]
RP   PHOSPHORYLATION, DEPHOSPHORYLATION BY PTPN6, AND ENZYME REGULATION.
RX   PubMed=10458769;
RX   DOI=10.1002/(SICI)1521-4141(199908)29:08<2539::AID-IMMU2539>3.0.CO;2-M;
RA   Brockdorff J., Williams S., Couture C., Mustelin T.;
RT   "Dephosphorylation of ZAP-70 and inhibition of T cell activation by
RT   activated SHP1.";
RL   Eur. J. Immunol. 29:2539-2550(1999).
RN   [12]
RP   INTERACTION WITH SLA.
RX   PubMed=10449770; DOI=10.1073/pnas.96.17.9775;
RA   Tang J., Sawasdikosol S., Chang J.-H., Burakoff S.J.;
RT   "SLAP, a dimeric adapter protein, plays a functional role in T cell
RT   receptor signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:9775-9780(1999).
RN   [13]
RP   INTERACTION WITH FCRL3.
RX   PubMed=11162587; DOI=10.1006/bbrc.2000.4213;
RA   Xu M.-J., Zhao R., Zhao Z.J.;
RT   "Molecular cloning and characterization of SPAP1, an inhibitory
RT   receptor.";
RL   Biochem. Biophys. Res. Commun. 280:768-775(2001).
RN   [14]
RP   FUNCTION IN B-CELL RECEPTOR SIGNALING PATHWAY, AND FUNCTION IN
RP   PHOSPHORYLATION OF BLNK.
RX   PubMed=12456653; DOI=10.1093/emboj/cdf658;
RA   Chiu C.W., Dalton M., Ishiai M., Kurosaki T., Chan A.C.;
RT   "BLNK: molecular scaffolding through 'cis'-mediated organization of
RT   signaling proteins.";
RL   EMBO J. 21:6461-6472(2002).
RN   [15]
RP   FUNCTION IN CELL ADHESION, AND INTERACTION WITH SELPLG AND MSN.
RX   PubMed=12387735; DOI=10.1016/S1074-7613(02)00420-X;
RA   Urzainqui A., Serrador J.M., Viedma F., Yanez-Mo M., Rodriguez A.,
RA   Corbi A.L., Alonso-Lebrero J.L., Luque A., Deckert M., Vazquez J.,
RA   Sanchez-Madrid F.;
RT   "ITAM-based interaction of ERM proteins with Syk mediates signaling by
RT   the leukocyte adhesion receptor PSGL-1.";
RL   Immunity 17:401-412(2002).
RN   [16]
RP   INTERACTION WITH ITGB3.
RX   PubMed=11940607; DOI=10.1083/jcb.200112113;
RA   Obergfell A., Eto K., Mocsai A., Buensuceso C., Moores S.L.,
RA   Brugge J.S., Lowell C.A., Shattil S.J.;
RT   "Coordinate interactions of Csk, Src, and Syk kinases with
RT   [alpha]IIb[beta]3 initiate integrin signaling to the cytoskeleton.";
RL   J. Cell Biol. 157:265-275(2002).
RN   [17]
RP   FUNCTION IN PHOSPHORYLATION OF LCP2.
RX   PubMed=15388330; DOI=10.1016/j.febslet.2004.07.090;
RA   Shim E.K., Moon C.S., Lee G.Y., Ha Y.J., Chae S.K., Lee J.R.;
RT   "Association of the Src homology 2 domain-containing leukocyte
RT   phosphoprotein of 76 kD (SLP-76) with the p85 subunit of
RT   phosphoinositide 3-kinase.";
RL   FEBS Lett. 575:35-40(2004).
RN   [18]
RP   INTERACTION WITH BLNK, ENZYME REGULATION, MUTAGENESIS OF TYR-630, AND
RP   PHOSPHORYLATION AT TYR-630.
RX   PubMed=18369315; DOI=10.1038/emboj.2008.62;
RA   Kulathu Y., Hobeika E., Turchinovich G., Reth M.;
RT   "The kinase Syk as an adaptor controlling sustained calcium signalling
RT   and B-cell development.";
RL   EMBO J. 27:1333-1344(2008).
RN   [19]
RP   ENZYME REGULATION.
RX   PubMed=18818202; DOI=10.1074/jbc.M806340200;
RA   Tsang E., Giannetti A.M., Shaw D., Dinh M., Tse J.K., Gandhi S.,
RA   Ho H., Wang S., Papp E., Bradshaw J.M.;
RT   "Molecular mechanism of the Syk activation switch.";
RL   J. Biol. Chem. 283:32650-32659(2008).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-323, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-28, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [23]
RP   INTERACTION WITH CLEC1B.
RX   PubMed=20154219; DOI=10.1182/blood-2009-08-237834;
RA   Hughes C.E., Pollitt A.Y., Mori J., Eble J.A., Tomlinson M.G.,
RA   Hartwig J.H., O'Callaghan C.A., Fuetterer K., Watson S.P.;
RT   "CLEC-2 activates Syk through dimerization.";
RL   Blood 115:2947-2955(2010).
RN   [24]
RP   INTERACTION WITH USP25, AND FUNCTION.
RX   PubMed=19909739; DOI=10.1016/j.yexcr.2009.10.023;
RA   Cholay M., Reverdy C., Benarous R., Colland F., Daviet L.;
RT   "Functional interaction between the ubiquitin-specific protease 25 and
RT   the SYK tyrosine kinase.";
RL   Exp. Cell Res. 316:667-675(2010).
RN   [25]
RP   INTERACTION WITH FLNA.
RX   PubMed=20713593; DOI=10.1084/jem.20100222;
RA   Falet H., Pollitt A.Y., Begonja A.J., Weber S.E., Duerschmied D.,
RA   Wagner D.D., Watson S.P., Hartwig J.H.;
RT   "A novel interaction between FlnA and Syk regulates platelet ITAM-
RT   mediated receptor signaling and function.";
RL   J. Exp. Med. 207:1967-1979(2010).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [27]
RP   PHOSPHORYLATION AT TYR-28; SER-44; TYR-47; TYR-131; SER-202; THR-256;
RP   SER-295; TYR-296; SER-297; SER-316; THR-317; SER-319; TYR-323;
RP   THR-345; TYR-348; SER-350; TYR-352; TYR-364; SER-379; THR-384;
RP   TYR-484; TYR-507; TYR-525; TYR-526; THR-530; SER-579; THR-582;
RP   TYR-629; TYR-630 AND TYR-631, INTERACTION WITH YWHAG, AND MUTAGENESIS
RP   OF SER-297.
RC   TISSUE=B-cell;
RX   PubMed=21469132; DOI=10.1002/eji.201041326;
RA   Bohnenberger H., Oellerich T., Engelke M., Hsiao H.H., Urlaub H.,
RA   Wienands J.;
RT   "Complex phosphorylation dynamics control the composition of the Syk
RT   interactome in B cells.";
RL   Eur. J. Immunol. 41:1550-1562(2011).
RN   [28]
RP   INTERACTION WITH TNS2.
RX   PubMed=22019427; DOI=10.1016/j.bbamcr.2011.10.001;
RA   Moon K.D., Zhang X., Zhou Q., Geahlen R.L.;
RT   "The protein-tyrosine kinase Syk interacts with the C-terminal region
RT   of tensin2.";
RL   Biochim. Biophys. Acta 1823:199-205(2012).
RN   [29]
RP   INTERACTION WITH GCSAM.
RX   PubMed=23299888; DOI=10.1038/ncomms2334;
RA   Romero-Camarero I., Jiang X., Natkunam Y., Lu X., Vicente-Duenas C.,
RA   Gonzalez-Herrero I., Flores T., Garcia J.L., McNamara G., Kunder C.,
RA   Zhao S., Segura V., Fontan L., Martinez-Climent J.A.,
RA   Garcia-Criado F.J., Theis J.D., Dogan A., Campos-Sanchez E.,
RA   Green M.R., Alizadeh A.A., Cobaleda C., Sanchez-Garcia I.,
RA   Lossos I.S.;
RT   "Germinal centre protein HGAL promotes lymphoid hyperplasia and
RT   amyloidosis via BCR-mediated Syk activation.";
RL   Nat. Commun. 4:1338-1338(2013).
RN   [30]
RP   STRUCTURE BY NMR OF 163-265.
RX   PubMed=8590001; DOI=10.1016/S0969-2126(01)00242-8;
RA   Narula S.S., Yuan R.W., Adams S.E., Green O.M., Green J.,
RA   Philips T.B., Zydowsky L.D., Botfield M.C., Hatada M., Laird E.R.,
RA   Zoller M.J., Karas J.L., Dalgarno D.C.;
RT   "Solution structure of the C-terminal SH2 domain of the human tyrosine
RT   kinase Syk complexed with a phosphotyrosine pentapeptide.";
RL   Structure 3:1061-1073(1995).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF SH2 DOMAINS IN COMPLEX WITH
RP   CD3E PHOSPHORYLATED ITAM DOMAIN.
RX   PubMed=9698567; DOI=10.1006/jmbi.1998.1964;
RA   Fuetterer K., Wong J., Grucza R.A., Chan A.C., Waksman G.;
RT   "Structural basis for Syk tyrosine kinase ubiquity in signal
RT   transduction pathways revealed by the crystal structure of its
RT   regulatory SH2 domains bound to a dually phosphorylated ITAM
RT   peptide.";
RL   J. Mol. Biol. 281:523-537(1998).
CC   -!- FUNCTION: Non-receptor tyrosine kinase which mediates signal
CC       transduction downstream of a variety of transmembrane receptors
CC       including classical immunoreceptors like the B-cell receptor
CC       (BCR). Regulates several biological processes including innate and
CC       adaptive immunity, cell adhesion, osteoclast maturation, platelet
CC       activation and vascular development. Assembles into signaling
CC       complexes with activated receptors at the plasma membrane via
CC       interaction between its SH2 domains and the receptor tyrosine-
CC       phosphorylated ITAM domains. The association with the receptor can
CC       also be indirect and mediated by adapter proteins containing ITAM
CC       or partial hemITAM domains. The phosphorylation of the ITAM
CC       domains is generally mediated by SRC subfamily kinases upon
CC       engagement of the receptor. More rarely signal transduction via
CC       SYK could be ITAM-independent. Direct downstream effectors
CC       phosphorylated by SYK include VAV1, PLCG1, PI-3-kinase, LCP2 and
CC       BLNK. Initially identified as essential in B-cell receptor (BCR)
CC       signaling, it is necessary for the maturation of B-cells most
CC       probably at the pro-B to pre-B transition. Activated upon BCR
CC       engagement, it phosphorylates and activates BLNK an adapter
CC       linking the activated BCR to downstream signaling adapters and
CC       effectors. It also phosphorylates and activates PLCG1 and the PKC
CC       signaling pathway. It also phosphorylates BTK and regulates its
CC       activity in B-cell antigen receptor (BCR)-coupled signaling. In
CC       addition to its function downstream of BCR plays also a role in T-
CC       cell receptor signaling. Plays also a crucial role in the innate
CC       immune response to fungal, bacterial and viral pathogens. It is
CC       for instance activated by the membrane lectin CLEC7A. Upon
CC       stimulation by fungal proteins, CLEC7A together with SYK activates
CC       immune cells inducing the production of ROS. Also activates the
CC       inflammasome and NF-kappa-B-mediated transcription of chemokines
CC       and cytokines in presence of pathogens. Regulates neutrophil
CC       degranulation and phagocytosis through activation of the MAPK
CC       signaling cascade. Also mediates the activation of dendritic cells
CC       by cell necrosis stimuli. Also involved in mast cells activation.
CC       Also functions downstream of receptors mediating cell adhesion.
CC       Relays for instance, integrin-mediated neutrophils and macrophages
CC       activation and P-selectin receptor/SELPG-mediated recruitment of
CC       leukocytes to inflammatory loci. Plays also a role in non-immune
CC       processes. It is for instance involved in vascular development
CC       where it may regulate blood and lymphatic vascular separation. It
CC       is also required for osteoclast development and function.
CC       Functions in the activation of platelets by collagen, mediating
CC       PLCG2 phosphorylation and activation. May be coupled to the
CC       collagen receptor by the ITAM domain-containing FCER1G. Also
CC       activated by the membrane lectin CLEC1B that is required for
CC       activation of platelets by PDPN/podoplanin. Involved in platelet
CC       adhesion being activated by ITGB3 engaged by fibrinogen. Together
CC       with CEACAM20, enhances production of the cytokine CXCL8/IL-8 via
CC       the NFKB pathway and may thus have a role in the intestinal immune
CC       response (By similarity). {ECO:0000250|UniProtKB:P48025,
CC       ECO:0000269|PubMed:12387735, ECO:0000269|PubMed:12456653,
CC       ECO:0000269|PubMed:15388330, ECO:0000269|PubMed:19909739,
CC       ECO:0000269|PubMed:8657103, ECO:0000269|PubMed:9535867}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: Autoinhibited. Intramolecular binding of the
CC       interdomains A and B (also called linker region) to parts of the
CC       catalytic domain keep the catalytic center in an inactive
CC       conformation. The phosphorylation of the interdomains or the
CC       binding of the SH2 domains with dually phosphorylated ITAM domains
CC       on transmembrane proteins disrupt those intramolecular
CC       interactions allowing the kinase domain to adopt an active
CC       conformation. The phosphorylation of SYK and of the ITAM domains
CC       which is responsible for SYK activation is essentially mediated by
CC       SRC subfamily kinases, like LYN, upon transmembrane receptors
CC       engagement. May also be negatively regulated by PTPN6 through
CC       dephosphorylation. Downstream signaling adapters and intermediates
CC       like BLNK or RHOH may mediate positive and/or negative feedback
CC       regulation. Negatively regulated by CBL and CBLB through
CC       ubiquitination and probable degradation. Phosphorylates SH3BP2
CC       which in turn may regulate SYK through LYN (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with LYN; phosphorylates SYK (By similarity).
CC       Interacts with RHOH (phosphorylated); regulates mast cells
CC       activation (By similarity). Interacts with NFAM1 (phosphorylated);
CC       probably involved in BCR signaling (By similarity). Interacts with
CC       VAV1 (via SH2 domain); phosphorylates VAV1 upon BCR activation.
CC       Interacts with GAB2 (phosphorylated); probably involved in IgE Fc
CC       receptor signaling (By similarity). Interacts (via its SH2
CC       domains) with CD79A (via its phosphorylated ITAM domain); the
CC       interaction stimulates SYK autophosphorylation and activation (By
CC       similarity). Interacts with FCRL3. Interacts (via SH2 domains)
CC       with FCER1G (via ITAM domain); activates SYK and mediates
CC       neutrophils and macrophages integrin-mediated activation (By
CC       similarity). Interacts with ITGB2 and FGR; involved in ITGB2
CC       downstream signaling (By similarity). Interacts with ITGB3; upon
CC       activation by ITGB3 promotes platelet adhesion. Interacts (via SH2
CC       domains) with TYROBP (via ITAM domain); involved in neutrophils
CC       and macrophages integrin-mediated activation (By similarity).
CC       Interacts with MSN and SELPLG; mediates the selectin-dependent
CC       activation of SYK by SELPLG. Interacts with BLNK (via SH2 domain).
CC       Interacts (via the second SH2 domain) with USP25 (via C-terminus);
CC       phosphorylates USP25 and regulates USP25 intracellular levels.
CC       Interacts (via SH2 domains) with CLEC1B (dimer). Interacts with
CC       CLEC7A; participates in leukocyte activation in presence of fungal
CC       pathogens. Interacts (phosphorylated) with SLA; may regulate SYK
CC       through CBL recruitment. Interacts with YWHAG; attenuates BCR-
CC       induced membrane translocation and activation of SYK. Interacts
CC       with Epstein-Barr virus LMP2A. Interacts (via SH2 domains) with
CC       GCSAM; the interaction increases after B-cell receptor
CC       stimulation, resulting in enhanced SYK autophosphorylation and
CC       activity. Interacts with TNS2; leading to the phosphorylation of
CC       SYK (PubMed:22019427). Interacts with FLNA (via filamin repeat 5);
CC       docks SYK to the plasma membrane (PubMed:20713593). Interacts with
CC       CEACAM1; lipopolysaccharide activated neutrophils induce
CC       phosphorylation of SYK resulting in the formation of a complex
CC       including TLR4 and the phosphorylated form of SYK and CEACAM1,
CC       which in turn, recruits PTPN6 that dephosphorylates SYK, reducing
CC       the production of reactive oxygen species (ROS) and lysosome
CC       disruption, leading to a reduction of the inflammasome activity
CC       (By similarity). Interacts (via SH2 domains) with CEACAM20
CC       (phosphorylated form); the interaction further enhances CEACAM20
CC       phosphorylation (By similarity). {ECO:0000250,
CC       ECO:0000250|UniProtKB:P48025, ECO:0000269|PubMed:10449770,
CC       ECO:0000269|PubMed:11162587, ECO:0000269|PubMed:11940607,
CC       ECO:0000269|PubMed:12387735, ECO:0000269|PubMed:18369315,
CC       ECO:0000269|PubMed:19909739, ECO:0000269|PubMed:20154219,
CC       ECO:0000269|PubMed:20713593, ECO:0000269|PubMed:21469132,
CC       ECO:0000269|PubMed:22019427, ECO:0000269|PubMed:23299888,
CC       ECO:0000269|PubMed:7895172, ECO:0000269|PubMed:8657103,
CC       ECO:0000269|PubMed:8986718, ECO:0000269|PubMed:9535867,
CC       ECO:0000269|PubMed:9698567, ECO:0000269|PubMed:9857068}.
CC   -!- INTERACTION:
CC       P22681:CBL; NbExp=2; IntAct=EBI-78302, EBI-518228;
CC       P20273:CD22; NbExp=4; IntAct=EBI-78302, EBI-78277;
CC       P11049:CD37; NbExp=3; IntAct=EBI-78302, EBI-6139068;
CC       P07766:CD3E; NbExp=6; IntAct=EBI-78302, EBI-1211297;
CC       P00533:EGFR; NbExp=6; IntAct=EBI-78302, EBI-297353;
CC       P04626:ERBB2; NbExp=7; IntAct=EBI-78302, EBI-641062;
CC       P21860:ERBB3; NbExp=6; IntAct=EBI-78302, EBI-720706;
CC       Q96IP4:FAM46A; NbExp=3; IntAct=EBI-78302, EBI-954084;
CC       P30273:FCER1G; NbExp=2; IntAct=EBI-78302, EBI-515289;
CC       P36888:FLT3; NbExp=21; IntAct=EBI-78302, EBI-3946257;
CC       Q13480:GAB1; NbExp=4; IntAct=EBI-78302, EBI-517684;
CC       P06239:LCK; NbExp=7; IntAct=EBI-78302, EBI-1348;
CC       P08581:MET; NbExp=3; IntAct=EBI-78302, EBI-1039152;
CC       P19174:PLCG1; NbExp=4; IntAct=EBI-78302, EBI-79387;
CC       Q9NP31:SH2D2A; NbExp=3; IntAct=EBI-78302, EBI-490630;
CC       P40763:STAT3; NbExp=6; IntAct=EBI-78302, EBI-518675;
CC       P54274:TERF1; NbExp=2; IntAct=EBI-78302, EBI-710997;
CC       Q8TF42:UBASH3B; NbExp=2; IntAct=EBI-78302, EBI-1380492;
CC       Q9UHP3:USP25; NbExp=6; IntAct=EBI-78302, EBI-2513462;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}. Cytoplasm,
CC       cytosol {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long;
CC         IsoId=P43405-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=P43405-2; Sequence=VSP_005010;
CC   -!- TISSUE SPECIFICITY: Widely expressed in hematopoietic cells (at
CC       protein level). Within the B-cells compartment it is for instance
CC       expressed for pro-B-cells to plasma cells.
CC       {ECO:0000269|PubMed:8163536}.
CC   -!- DOMAIN: The SH2 domains mediate the interaction of SYK with the
CC       phosphorylated ITAM domains of transmembrane proteins. Some
CC       proteins like CLEC1B have a partial ITAM domain (also called
CC       hemITAM) containing a single YxxL motif. The interaction with SYK
CC       requires CLEC1B homodimerization.
CC   -!- PTM: Ubiquitinated by CBLB after BCR activation; which promotes
CC       proteasomal degradation. {ECO:0000250}.
CC   -!- PTM: Autophosphorylated. Phosphorylated on tyrosine residues by
CC       LYN following receptors engagement. Phosphorylation on Tyr-323
CC       creates a binding site for CBL, an adapter protein that serves as
CC       a negative regulator of BCR-stimulated calcium ion signaling.
CC       Phosphorylation at Tyr-348 creates a binding site for VAV1.
CC       Phosphorylation on Tyr-348 and Tyr-352 enhances the
CC       phosphorylation and activation of phospholipase C-gamma and the
CC       early phase of calcium ion mobilization via a phosphoinositide 3-
CC       kinase-independent pathway (By similarity). Phosphorylation on
CC       Ser-297 is very common, it peaks 5 minutes after BCR stimulation,
CC       and creates a binding site for YWHAG. Phosphorylation at Tyr-630
CC       creates a binding site for BLNK. Dephosphorylated by PTPN6.
CC       {ECO:0000250, ECO:0000269|PubMed:10458769,
CC       ECO:0000269|PubMed:18369315, ECO:0000269|PubMed:21469132}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. SYK/ZAP-70 subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/SYKID394.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z29630; CAA82737.1; -; mRNA.
DR   EMBL; L28824; AAA36526.1; -; mRNA.
DR   EMBL; AL354862; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC001645; AAH01645.1; -; mRNA.
DR   EMBL; BC011399; AAH11399.1; -; mRNA.
DR   EMBL; BC002962; AAH02962.1; -; mRNA.
DR   EMBL; X73568; CAA51970.1; -; mRNA.
DR   CCDS; CCDS47992.1; -. [P43405-2]
DR   CCDS; CCDS6688.1; -. [P43405-1]
DR   PIR; A53596; A53596.
DR   RefSeq; NP_001128524.1; NM_001135052.3. [P43405-2]
DR   RefSeq; NP_001167638.1; NM_001174167.2. [P43405-1]
DR   RefSeq; NP_001167639.1; NM_001174168.2. [P43405-2]
DR   RefSeq; NP_003168.2; NM_003177.6. [P43405-1]
DR   RefSeq; XP_005252204.1; XM_005252147.3. [P43405-1]
DR   RefSeq; XP_011517248.1; XM_011518946.2. [P43405-1]
DR   UniGene; Hs.371720; -.
DR   PDB; 1A81; X-ray; 3.00 A; A/C/E/G/I/K=9-262.
DR   PDB; 1CSY; NMR; -; A=163-265.
DR   PDB; 1CSZ; NMR; -; A=163-265.
DR   PDB; 1XBA; X-ray; 2.00 A; A=356-635.
DR   PDB; 1XBB; X-ray; 1.57 A; A=356-635.
DR   PDB; 1XBC; X-ray; 2.00 A; A=356-635.
DR   PDB; 3BUW; X-ray; 1.45 A; A/C=317-329.
DR   PDB; 3EMG; X-ray; 2.60 A; A=349-635.
DR   PDB; 3FQE; X-ray; 2.50 A; A=356-635.
DR   PDB; 3FQH; X-ray; 2.26 A; A/B=356-635.
DR   PDB; 3FQS; X-ray; 2.10 A; A=356-635.
DR   PDB; 3SRV; X-ray; 1.95 A; A/B=360-635.
DR   PDB; 3TUB; X-ray; 2.23 A; A=343-635.
DR   PDB; 3TUC; X-ray; 2.10 A; A=343-635.
DR   PDB; 3TUD; X-ray; 2.33 A; A=343-635.
DR   PDB; 3VF8; X-ray; 2.08 A; A=343-635.
DR   PDB; 3VF9; X-ray; 2.30 A; A=343-635.
DR   PDB; 4DFL; X-ray; 1.98 A; A=363-635.
DR   PDB; 4DFN; X-ray; 2.48 A; A=363-635.
DR   PDB; 4F4P; X-ray; 2.37 A; A=365-635.
DR   PDB; 4FL1; X-ray; 1.79 A; A=356-635.
DR   PDB; 4FL2; X-ray; 2.19 A; A=1-635.
DR   PDB; 4FL3; X-ray; 1.90 A; A=1-635.
DR   PDB; 4FYN; X-ray; 2.32 A; A=356-635.
DR   PDB; 4FYO; X-ray; 1.40 A; A=356-635.
DR   PDB; 4FZ6; X-ray; 1.85 A; A=356-635.
DR   PDB; 4FZ7; X-ray; 1.75 A; A=356-635.
DR   PDB; 4GFG; X-ray; 2.35 A; A=356-635.
DR   PDB; 4I0R; X-ray; 2.10 A; A=356-635.
DR   PDB; 4I0S; X-ray; 1.98 A; A=356-635.
DR   PDB; 4I0T; X-ray; 1.70 A; A=356-635.
DR   PDB; 4PUZ; X-ray; 2.08 A; A/B=356-635.
DR   PDB; 4PV0; X-ray; 2.00 A; A=363-635.
DR   PDB; 4PX6; X-ray; 1.60 A; A=356-635.
DR   PDB; 4RSS; X-ray; 1.83 A; A=356-635.
DR   PDB; 4RX7; X-ray; 1.80 A; A=356-635.
DR   PDB; 4RX8; X-ray; 1.59 A; A=356-635.
DR   PDB; 4RX9; X-ray; 1.75 A; A=356-635.
DR   PDB; 4WNM; X-ray; 2.50 A; A=343-635.
DR   PDB; 4XG2; X-ray; 2.21 A; A=356-635.
DR   PDB; 4XG3; X-ray; 2.30 A; A/B=356-635.
DR   PDB; 4XG4; X-ray; 2.30 A; A=356-635.
DR   PDB; 4XG6; X-ray; 2.40 A; A=356-635.
DR   PDB; 4XG7; X-ray; 1.76 A; A=356-635.
DR   PDB; 4XG8; X-ray; 2.40 A; A/C=356-635.
DR   PDB; 4XG9; X-ray; 2.91 A; A/B=356-635.
DR   PDB; 4YJO; X-ray; 1.60 A; A=355-635.
DR   PDB; 4YJP; X-ray; 1.83 A; A=355-635.
DR   PDB; 4YJQ; X-ray; 1.34 A; A=355-635.
DR   PDB; 4YJR; X-ray; 1.32 A; A=355-635.
DR   PDB; 4YJS; X-ray; 2.22 A; A=355-635.
DR   PDB; 4YJT; X-ray; 1.52 A; A=355-635.
DR   PDB; 4YJU; X-ray; 1.67 A; A=355-635.
DR   PDB; 4YJV; X-ray; 1.65 A; A=355-635.
DR   PDB; 5C26; X-ray; 1.95 A; A=343-635.
DR   PDB; 5C27; X-ray; 2.15 A; A=343-635.
DR   PDB; 5CXH; X-ray; 1.90 A; A=356-635.
DR   PDB; 5CXZ; X-ray; 1.70 A; A=356-635.
DR   PDB; 5CY3; X-ray; 1.76 A; A=356-635.
DR   PDB; 5GHV; X-ray; 2.80 A; A/B=356-635.
DR   PDB; 5LMA; X-ray; 1.43 A; A=360-635.
DR   PDB; 5LMB; X-ray; 1.95 A; A/B=360-635.
DR   PDB; 5T68; X-ray; 2.93 A; A/B=356-635.
DR   PDB; 5TIU; X-ray; 1.49 A; A=356-635.
DR   PDB; 5TR6; X-ray; 1.93 A; A=356-635.
DR   PDB; 5TT7; X-ray; 1.77 A; A=356-635.
DR   PDBsum; 1A81; -.
DR   PDBsum; 1CSY; -.
DR   PDBsum; 1CSZ; -.
DR   PDBsum; 1XBA; -.
DR   PDBsum; 1XBB; -.
DR   PDBsum; 1XBC; -.
DR   PDBsum; 3BUW; -.
DR   PDBsum; 3EMG; -.
DR   PDBsum; 3FQE; -.
DR   PDBsum; 3FQH; -.
DR   PDBsum; 3FQS; -.
DR   PDBsum; 3SRV; -.
DR   PDBsum; 3TUB; -.
DR   PDBsum; 3TUC; -.
DR   PDBsum; 3TUD; -.
DR   PDBsum; 3VF8; -.
DR   PDBsum; 3VF9; -.
DR   PDBsum; 4DFL; -.
DR   PDBsum; 4DFN; -.
DR   PDBsum; 4F4P; -.
DR   PDBsum; 4FL1; -.
DR   PDBsum; 4FL2; -.
DR   PDBsum; 4FL3; -.
DR   PDBsum; 4FYN; -.
DR   PDBsum; 4FYO; -.
DR   PDBsum; 4FZ6; -.
DR   PDBsum; 4FZ7; -.
DR   PDBsum; 4GFG; -.
DR   PDBsum; 4I0R; -.
DR   PDBsum; 4I0S; -.
DR   PDBsum; 4I0T; -.
DR   PDBsum; 4PUZ; -.
DR   PDBsum; 4PV0; -.
DR   PDBsum; 4PX6; -.
DR   PDBsum; 4RSS; -.
DR   PDBsum; 4RX7; -.
DR   PDBsum; 4RX8; -.
DR   PDBsum; 4RX9; -.
DR   PDBsum; 4WNM; -.
DR   PDBsum; 4XG2; -.
DR   PDBsum; 4XG3; -.
DR   PDBsum; 4XG4; -.
DR   PDBsum; 4XG6; -.
DR   PDBsum; 4XG7; -.
DR   PDBsum; 4XG8; -.
DR   PDBsum; 4XG9; -.
DR   PDBsum; 4YJO; -.
DR   PDBsum; 4YJP; -.
DR   PDBsum; 4YJQ; -.
DR   PDBsum; 4YJR; -.
DR   PDBsum; 4YJS; -.
DR   PDBsum; 4YJT; -.
DR   PDBsum; 4YJU; -.
DR   PDBsum; 4YJV; -.
DR   PDBsum; 5C26; -.
DR   PDBsum; 5C27; -.
DR   PDBsum; 5CXH; -.
DR   PDBsum; 5CXZ; -.
DR   PDBsum; 5CY3; -.
DR   PDBsum; 5GHV; -.
DR   PDBsum; 5LMA; -.
DR   PDBsum; 5LMB; -.
DR   PDBsum; 5T68; -.
DR   PDBsum; 5TIU; -.
DR   PDBsum; 5TR6; -.
DR   PDBsum; 5TT7; -.
DR   ProteinModelPortal; P43405; -.
DR   SMR; P43405; -.
DR   BioGrid; 112717; 108.
DR   DIP; DIP-253N; -.
DR   IntAct; P43405; 43.
DR   MINT; MINT-148486; -.
DR   STRING; 9606.ENSP00000364898; -.
DR   BindingDB; P43405; -.
DR   ChEMBL; CHEMBL2599; -.
DR   DrugBank; DB08846; Ellagic Acid.
DR   DrugBank; DB02010; Staurosporine.
DR   GuidetoPHARMACOLOGY; 2230; -.
DR   iPTMnet; P43405; -.
DR   PhosphoSitePlus; P43405; -.
DR   BioMuta; SYK; -.
DR   DMDM; 1174527; -.
DR   EPD; P43405; -.
DR   MaxQB; P43405; -.
DR   PaxDb; P43405; -.
DR   PeptideAtlas; P43405; -.
DR   PRIDE; P43405; -.
DR   DNASU; 6850; -.
DR   Ensembl; ENST00000375746; ENSP00000364898; ENSG00000165025. [P43405-1]
DR   Ensembl; ENST00000375747; ENSP00000364899; ENSG00000165025. [P43405-2]
DR   Ensembl; ENST00000375751; ENSP00000364904; ENSG00000165025. [P43405-2]
DR   Ensembl; ENST00000375754; ENSP00000364907; ENSG00000165025. [P43405-1]
DR   GeneID; 6850; -.
DR   KEGG; hsa:6850; -.
DR   UCSC; uc004aqz.4; human. [P43405-1]
DR   CTD; 6850; -.
DR   DisGeNET; 6850; -.
DR   GeneCards; SYK; -.
DR   HGNC; HGNC:11491; SYK.
DR   HPA; CAB007773; -.
DR   HPA; HPA001384; -.
DR   MIM; 600085; gene.
DR   neXtProt; NX_P43405; -.
DR   OpenTargets; ENSG00000165025; -.
DR   PharmGKB; PA36273; -.
DR   eggNOG; ENOG410IH0T; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118799; -.
DR   HOGENOM; HOG000113264; -.
DR   HOVERGEN; HBG001540; -.
DR   InParanoid; P43405; -.
DR   KO; K05855; -.
DR   OMA; ICLLKKP; -.
DR   OrthoDB; EOG091G07KU; -.
DR   PhylomeDB; P43405; -.
DR   TreeFam; TF351629; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-2029481; FCGR activation.
DR   Reactome; R-HSA-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-HSA-2029485; Role of phospholipids in phagocytosis.
DR   Reactome; R-HSA-2424491; DAP12 signaling.
DR   Reactome; R-HSA-2454202; Fc epsilon receptor (FCERI) signaling.
DR   Reactome; R-HSA-2730905; Role of LAT2/NTAL/LAB on calcium mobilization.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization.
DR   Reactome; R-HSA-354192; Integrin alphaIIb beta3 signaling.
DR   Reactome; R-HSA-451927; Interleukin-2 signaling.
DR   Reactome; R-HSA-5607764; CLEC7A (Dectin-1) signaling.
DR   Reactome; R-HSA-5621480; Dectin-2 family.
DR   Reactome; R-HSA-912631; Regulation of signaling by CBL.
DR   Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   SignaLink; P43405; -.
DR   SIGNOR; P43405; -.
DR   ChiTaRS; SYK; human.
DR   EvolutionaryTrace; P43405; -.
DR   GeneWiki; Syk; -.
DR   GenomeRNAi; 6850; -.
DR   PRO; PR:P43405; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000165025; -.
DR   CleanEx; HS_SYK; -.
DR   ExpressionAtlas; P43405; baseline and differential.
DR   Genevisible; P43405; HS.
DR   GO; GO:0019815; C:B cell receptor complex; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0032009; C:early phagosome; ISS:UniProtKB.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043234; C:protein complex; IDA:MGI.
DR   GO; GO:0042101; C:T cell receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005178; F:integrin binding; IPI:UniProtKB.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0019902; F:phosphatase binding; IEA:Ensembl.
DR   GO; GO:0001784; F:phosphotyrosine binding; IPI:CAFA.
DR   GO; GO:0004672; F:protein kinase activity; IDA:CACAO.
DR   GO; GO:0019901; F:protein kinase binding; IEA:Ensembl.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:MGI.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome.
DR   GO; GO:0042169; F:SH2 domain binding; IEA:Ensembl.
DR   GO; GO:0004716; F:signal transducer, downstream of receptor, with protein tyrosine kinase activity; IEA:Ensembl.
DR   GO; GO:0035325; F:Toll-like receptor binding; IEA:Ensembl.
DR   GO; GO:0007257; P:activation of JUN kinase activity; IEA:Ensembl.
DR   GO; GO:0002250; P:adaptive immune response; ISS:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0009887; P:animal organ morphogenesis; TAS:ProtInc.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0043366; P:beta selection; IEA:Ensembl.
DR   GO; GO:0048514; P:blood vessel morphogenesis; ISS:UniProtKB.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0071404; P:cellular response to low-density lipoprotein particle stimulus; ISS:UniProtKB.
DR   GO; GO:0071226; P:cellular response to molecule of fungal origin; ISS:UniProtKB.
DR   GO; GO:0038063; P:collagen-activated tyrosine kinase receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0042742; P:defense response to bacterium; ISS:UniProtKB.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR   GO; GO:0045087; P:innate immune response; ISS:UniProtKB.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0002366; P:leukocyte activation involved in immune response; ISS:UniProtKB.
DR   GO; GO:0007159; P:leukocyte cell-cell adhesion; IDA:UniProtKB.
DR   GO; GO:0019370; P:leukotriene biosynthetic process; IEA:Ensembl.
DR   GO; GO:0001945; P:lymph vessel development; ISS:UniProtKB.
DR   GO; GO:0002281; P:macrophage activation involved in immune response; ISS:UniProtKB.
DR   GO; GO:0002283; P:neutrophil activation involved in immune response; ISS:UniProtKB.
DR   GO; GO:0030593; P:neutrophil chemotaxis; IDA:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0046638; P:positive regulation of alpha-beta T cell differentiation; IEA:Ensembl.
DR   GO; GO:0046641; P:positive regulation of alpha-beta T cell proliferation; IBA:GO_Central.
DR   GO; GO:0045579; P:positive regulation of B cell differentiation; IMP:CACAO.
DR   GO; GO:0045780; P:positive regulation of bone resorption; ISS:UniProtKB.
DR   GO; GO:0050850; P:positive regulation of calcium-mediated signaling; IEA:Ensembl.
DR   GO; GO:0033630; P:positive regulation of cell adhesion mediated by integrin; ISS:UniProtKB.
DR   GO; GO:0050715; P:positive regulation of cytokine secretion; IEA:Ensembl.
DR   GO; GO:0045588; P:positive regulation of gamma-delta T cell differentiation; IEA:Ensembl.
DR   GO; GO:0045425; P:positive regulation of granulocyte macrophage colony-stimulating factor biosynthetic process; IEA:Ensembl.
DR   GO; GO:0045401; P:positive regulation of interleukin-3 biosynthetic process; IEA:Ensembl.
DR   GO; GO:0043306; P:positive regulation of mast cell degranulation; IBA:GO_Central.
DR   GO; GO:1900086; P:positive regulation of peptidyl-tyrosine autophosphorylation; IEA:Ensembl.
DR   GO; GO:0002092; P:positive regulation of receptor internalization; IEA:Ensembl.
DR   GO; GO:0032481; P:positive regulation of type I interferon production; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:CACAO.
DR   GO; GO:0031623; P:receptor internalization; ISS:UniProtKB.
DR   GO; GO:0090237; P:regulation of arachidonic acid secretion; ISS:UniProtKB.
DR   GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0043313; P:regulation of neutrophil degranulation; ISS:UniProtKB.
DR   GO; GO:0050764; P:regulation of phagocytosis; ISS:UniProtKB.
DR   GO; GO:0010543; P:regulation of platelet activation; ISS:UniProtKB.
DR   GO; GO:0090330; P:regulation of platelet aggregation; ISS:UniProtKB.
DR   GO; GO:0051090; P:regulation of sequence-specific DNA binding transcription factor activity; IMP:MGI.
DR   GO; GO:0032928; P:regulation of superoxide anion generation; ISS:UniProtKB.
DR   GO; GO:0010803; P:regulation of tumor necrosis factor-mediated signaling pathway; IMP:CACAO.
DR   GO; GO:0002554; P:serotonin secretion by platelet; ISS:UniProtKB.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0042991; P:transcription factor import into nucleus; IMP:MGI.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 1.10.930.10; -; 1.
DR   Gene3D; 3.30.505.10; -; 2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR023420; Kinase_SYK/ZAP-70_inter-SH2.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR012234; Tyr_kinase_non-rcpt_SYK/ZAP70.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 2.
DR   PIRSF; PIRSF000604; TyrPK_SYK; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF55550; SSF55550; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Alternative splicing; Angiogenesis;
KW   ATP-binding; Cell membrane; Complete proteome; Cytoplasm;
KW   Host-virus interaction; Immunity; Innate immunity; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Repeat; SH2 domain; Transferase; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   CHAIN         1    635       Tyrosine-protein kinase SYK.
FT                                /FTId=PRO_0000088165.
FT   DOMAIN       15    107       SH2 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      168    259       SH2 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      371    631       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     377    385       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      108    167       Interdomain A.
FT   REGION      260    370       Interdomain B.
FT   ACT_SITE    494    494       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     402    402       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES      28     28       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000269|PubMed:21469132}.
FT   MOD_RES      44     44       Phosphoserine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES      47     47       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES     131    131       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES     202    202       Phosphoserine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES     256    256       Phosphothreonine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES     295    295       Phosphoserine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES     296    296       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES     297    297       Phosphoserine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES     316    316       Phosphoserine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES     317    317       Phosphothreonine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES     319    319       Phosphoserine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES     323    323       Phosphotyrosine; by LYN.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000269|PubMed:21469132}.
FT   MOD_RES     345    345       Phosphothreonine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES     348    348       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES     350    350       Phosphoserine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES     352    352       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES     364    364       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES     379    379       Phosphoserine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES     384    384       Phosphothreonine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES     484    484       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES     507    507       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES     525    525       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES     526    526       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES     530    530       Phosphothreonine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES     546    546       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P48025}.
FT   MOD_RES     579    579       Phosphoserine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES     582    582       Phosphothreonine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES     629    629       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MOD_RES     630    630       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:18369315,
FT                                ECO:0000269|PubMed:21469132}.
FT   MOD_RES     631    631       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:21469132}.
FT   VAR_SEQ     283    305       Missing (in isoform Short).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_005010.
FT   VARIANT      45     45       R -> H (in dbSNP:rs16906862).
FT                                /FTId=VAR_033838.
FT   MUTAGEN     297    297       S->A: Abolishes YWHAG binding.
FT                                {ECO:0000269|PubMed:21469132}.
FT   MUTAGEN     630    630       Y->F: Loss of interaction with BLNK.
FT                                {ECO:0000269|PubMed:18369315}.
FT   CONFLICT    119    119       P -> A (in Ref. 5; CAA51970).
FT                                {ECO:0000305}.
FT   CONFLICT    250    250       G -> P (in Ref. 5; CAA51970).
FT                                {ECO:0000305}.
FT   HELIX        22     31       {ECO:0000244|PDB:4FL3}.
FT   STRAND       38     43       {ECO:0000244|PDB:4FL3}.
FT   STRAND       47     49       {ECO:0000244|PDB:4FL3}.
FT   STRAND       51     57       {ECO:0000244|PDB:4FL3}.
FT   STRAND       60     68       {ECO:0000244|PDB:4FL3}.
FT   STRAND       74     76       {ECO:0000244|PDB:4FL3}.
FT   STRAND       82     84       {ECO:0000244|PDB:4FL3}.
FT   HELIX        85     92       {ECO:0000244|PDB:4FL3}.
FT   STRAND       99    101       {ECO:0000244|PDB:4FL3}.
FT   HELIX       119    136       {ECO:0000244|PDB:4FL3}.
FT   HELIX       140    158       {ECO:0000244|PDB:4FL3}.
FT   HELIX       163    165       {ECO:0000244|PDB:4FL3}.
FT   STRAND      169    172       {ECO:0000244|PDB:1A81}.
FT   HELIX       175    183       {ECO:0000244|PDB:4FL3}.
FT   STRAND      184    186       {ECO:0000244|PDB:4FL3}.
FT   STRAND      187    189       {ECO:0000244|PDB:1CSY}.
FT   STRAND      192    201       {ECO:0000244|PDB:4FL3}.
FT   STRAND      203    209       {ECO:0000244|PDB:4FL3}.
FT   STRAND      212    220       {ECO:0000244|PDB:4FL3}.
FT   STRAND      221    224       {ECO:0000244|PDB:1CSY}.
FT   STRAND      226    228       {ECO:0000244|PDB:4FL3}.
FT   STRAND      229    231       {ECO:0000244|PDB:1CSY}.
FT   STRAND      234    236       {ECO:0000244|PDB:4FL3}.
FT   HELIX       237    244       {ECO:0000244|PDB:4FL3}.
FT   STRAND      251    253       {ECO:0000244|PDB:4FL3}.
FT   HELIX       342    344       {ECO:0000244|PDB:4FL3}.
FT   HELIX       346    348       {ECO:0000244|PDB:4FL2}.
FT   HELIX       351    353       {ECO:0000244|PDB:4FL2}.
FT   HELIX       360    363       {ECO:0000244|PDB:5TT7}.
FT   HELIX       367    369       {ECO:0000244|PDB:4YJR}.
FT   STRAND      370    372       {ECO:0000244|PDB:4YJR}.
FT   STRAND      377    380       {ECO:0000244|PDB:4YJT}.
FT   STRAND      384    391       {ECO:0000244|PDB:4YJR}.
FT   STRAND      393    409       {ECO:0000244|PDB:4YJR}.
FT   HELIX       411    424       {ECO:0000244|PDB:4YJR}.
FT   STRAND      435    449       {ECO:0000244|PDB:4YJR}.
FT   HELIX       456    462       {ECO:0000244|PDB:4YJR}.
FT   HELIX       468    487       {ECO:0000244|PDB:4YJR}.
FT   HELIX       497    499       {ECO:0000244|PDB:4YJR}.
FT   STRAND      500    504       {ECO:0000244|PDB:4YJR}.
FT   STRAND      507    510       {ECO:0000244|PDB:4YJR}.
FT   HELIX       513    515       {ECO:0000244|PDB:4RX7}.
FT   STRAND      524    527       {ECO:0000244|PDB:4YJR}.
FT   HELIX       536    538       {ECO:0000244|PDB:4YJR}.
FT   HELIX       541    546       {ECO:0000244|PDB:4YJR}.
FT   STRAND      548    550       {ECO:0000244|PDB:4YJR}.
FT   HELIX       551    566       {ECO:0000244|PDB:4YJR}.
FT   TURN        567    569       {ECO:0000244|PDB:4YJR}.
FT   TURN        572    575       {ECO:0000244|PDB:4YJR}.
FT   HELIX       578    586       {ECO:0000244|PDB:4YJR}.
FT   STRAND      589    591       {ECO:0000244|PDB:3SRV}.
FT   HELIX       599    608       {ECO:0000244|PDB:4YJR}.
FT   HELIX       613    615       {ECO:0000244|PDB:4YJR}.
FT   HELIX       619    624       {ECO:0000244|PDB:4YJR}.
SQ   SEQUENCE   635 AA;  72066 MW;  EAA6BDE65881FC68 CRC64;
     MASSGMADSA NHLPFFFGNI TREEAEDYLV QGGMSDGLYL LRQSRNYLGG FALSVAHGRK
     AHHYTIEREL NGTYAIAGGR THASPADLCH YHSQESDGLV CLLKKPFNRP QGVQPKTGPF
     EDLKENLIRE YVKQTWNLQG QALEQAIISQ KPQLEKLIAT TAHEKMPWFH GKISREESEQ
     IVLIGSKTNG KFLIRARDNN GSYALCLLHE GKVLHYRIDK DKTGKLSIPE GKKFDTLWQL
     VEHYSYKADG LLRVLTVPCQ KIGTQGNVNF GGRPQLPGSH PATWSAGGII SRIKSYSFPK
     PGHRKSSPAQ GNRQESTVSF NPYEPELAPW AADKGPQREA LPMDTEVYES PYADPEEIRP
     KEVYLDRKLL TLEDKELGSG NFGTVKKGYY QMKKVVKTVA VKILKNEAND PALKDELLAE
     ANVMQQLDNP YIVRMIGICE AESWMLVMEM AELGPLNKYL QQNRHVKDKN IIELVHQVSM
     GMKYLEESNF VHRDLAARNV LLVTQHYAKI SDFGLSKALR ADENYYKAQT HGKWPVKWYA
     PECINYYKFS SKSDVWSFGV LMWEAFSYGQ KPYRGMKGSE VTAMLEKGER MGCPAGCPRE
     MYDLMNLCWT YDVENRPGFA AVELRLRNYY YDVVN
//
